Global Orphan Drugs Market Size study & Forecast, by Drug Type (Biological, Non-biological) by Top Selling Drugs (Revlimid, Darzalex, Rituxan, Tafinlar, Ninlaro, Other), by Disease Type (Oncology, Hematology, Neurology, Cardiovascular, Other Disease Types) and Regional Analysis, 2023-2030
Global Orphan Drugs Market is valued approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Orphan drugs, also known as orphan medicinal products, are pharmaceutical drugs developed to treat rare diseases or conditions. The prevalence of rare diseases among the world's population has grown recently. Both emerging and industrialized nations have adopted policies to address this issue that encourage the discovery of medications for uncommon diseases and ensure that these medications are readily available. The Orphan Drugs market is expanding because of factors such as rising prevalence of rare diseases and favorable government policies.
According to the Genetic and Rare Diseases (GARD) Information Centre in May 2022, there are around 7,000 rare diseases, and one in ten Americans (nearly 30 million individuals) have one. Furthermore, according to statistics from 'GlobalGenes' that was updated in September 2021, more than 400 million people globally are affected by uncommon diseases. Inherent genetic causes for 80% of uncommon disorders have been found. Furthermore, according to the study 'Rare diseases: maintaining momentum' published in March 2022, drug companies invested USD 22.9 billion in total in research on rare disorders in 2021, a 28% increase from 2020. As a result, there are more prospects for new orphan medications due to rising prevalence and rising research and development spending on uncommon disease, which is ultimately driving the market growth. In addition, increasing research and development activities in the development of new therapies for rare diseases and strong product launches activities is creating a lucrative opportunity to the market. However, high per patient treatment cost and limited patient pool for clinical trials and product marketing stifles market growth throughout the forecast period of 2023-2030.
The key regions considered for the Global Orphan Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the dominance of branded products and the region's increasing disease prevalence. Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as rising target populations, an increase in the number of collaborations for product development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.
Major market player included in this report are:
Alexion Pharmaceuticals Inc
Bristol-Myers Squibb Company (Celgene Corporation)
Novartis AG
Pfizer Inc.
F. Hoffmann-La Roche Ltd
Takeda Pharmaceutical Company Limited
Amgen Inc.
Sanofi S.A
Johnson & Johnson Pvt Ltd
AstraZeneca Plc
Recent Developments in the Market:
In June 2022, The Food and medicine Administration (FDA) has designated ALX Oncology Holdings Inc.'s evorpacept, a next-generation CD47 blocker, as an orphan medicine for the treatment of acute myeloid leukaemia (AML).
In March 2021, The Food and Drug Administration has granted orphan drug classification to Intellia Therapeutics' CRISPR-edited T cell receptor (TCR) T-cell therapy for the treatment of acute myeloid leukaemia (AML).
Global Orphan Drugs Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered – Drug Type, Top Selling Drugs, Disease Type, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Customization Scope - Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Drug Typeofferings of key players. The detailed segments and sub-segment of the market are explained below:
By Drug Type:
Biological
Non-biological
By Top Selling Drugs:
Revlimid
Darzalex
Rituxan
Tafinlar
Ninlaro
Other
By Disease Type:
Oncology
Hematology
Neurology
Cardiovascular
Other Disease Types
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa
According to the Genetic and Rare Diseases (GARD) Information Centre in May 2022, there are around 7,000 rare diseases, and one in ten Americans (nearly 30 million individuals) have one. Furthermore, according to statistics from 'GlobalGenes' that was updated in September 2021, more than 400 million people globally are affected by uncommon diseases. Inherent genetic causes for 80% of uncommon disorders have been found. Furthermore, according to the study 'Rare diseases: maintaining momentum' published in March 2022, drug companies invested USD 22.9 billion in total in research on rare disorders in 2021, a 28% increase from 2020. As a result, there are more prospects for new orphan medications due to rising prevalence and rising research and development spending on uncommon disease, which is ultimately driving the market growth. In addition, increasing research and development activities in the development of new therapies for rare diseases and strong product launches activities is creating a lucrative opportunity to the market. However, high per patient treatment cost and limited patient pool for clinical trials and product marketing stifles market growth throughout the forecast period of 2023-2030.
The key regions considered for the Global Orphan Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the dominance of branded products and the region's increasing disease prevalence. Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as rising target populations, an increase in the number of collaborations for product development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.
Major market player included in this report are:
Alexion Pharmaceuticals Inc
Bristol-Myers Squibb Company (Celgene Corporation)
Novartis AG
Pfizer Inc.
F. Hoffmann-La Roche Ltd
Takeda Pharmaceutical Company Limited
Amgen Inc.
Sanofi S.A
Johnson & Johnson Pvt Ltd
AstraZeneca Plc
Recent Developments in the Market:
In June 2022, The Food and medicine Administration (FDA) has designated ALX Oncology Holdings Inc.'s evorpacept, a next-generation CD47 blocker, as an orphan medicine for the treatment of acute myeloid leukaemia (AML).
In March 2021, The Food and Drug Administration has granted orphan drug classification to Intellia Therapeutics' CRISPR-edited T cell receptor (TCR) T-cell therapy for the treatment of acute myeloid leukaemia (AML).
Global Orphan Drugs Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered – Drug Type, Top Selling Drugs, Disease Type, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Customization Scope - Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Drug Typeofferings of key players. The detailed segments and sub-segment of the market are explained below:
By Drug Type:
Biological
Non-biological
By Top Selling Drugs:
Revlimid
Darzalex
Rituxan
Tafinlar
Ninlaro
Other
By Disease Type:
Oncology
Hematology
Neurology
Cardiovascular
Other Disease Types
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa
CHAPTER 1. EXECUTIVE SUMMARY
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
1.2.1. Orphan Drugs Market, by Region, 2020-2030 (USD Billion)
1.2.2. Orphan Drugs Market, by Drug Type, 2020-2030 (USD Billion)
1.2.3. Orphan Drugs Market, by Top Selling Drugs, 2020-2030 (USD Billion)
1.2.4. Orphan Drugs Market, by Disease Type, 2020-2030 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
CHAPTER 2. GLOBAL ORPHAN DRUGS MARKET DEFINITION AND SCOPE
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Industry Evolution
2.2.2. Scope of the Study
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
CHAPTER 3. GLOBAL ORPHAN DRUGS MARKET DYNAMICS
3.1. Orphan Drugs Market Impact Analysis (2020-2030)
3.1.1. Market Drivers
3.1.1.1. Rising Prevalence of Rare Diseases
3.1.1.2. Favorable Government Policies
3.1.2. Market Challenges
3.1.2.1. High Per Patient Treatment Cost
3.1.2.2. Limited Patient Pool for Clinical Trials and Product Marketing
3.1.3. Market Opportunities
3.1.3.1. Increasing research and development activities in the development of new therapies for rare diseases
3.1.3.2. Strong Product Launches activities
CHAPTER 4. GLOBAL ORPHAN DRUGS MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Porter’s 5 Force Impact Analysis
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.3.5. Environmental
4.3.6. Legal
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. COVID-19 Impact Analysis
4.7. Disruptive Trends
4.8. Industry Expert Perspective
4.9. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL ORPHAN DRUGS MARKET, BY DRUG TYPE
5.1. Market Snapshot
5.2. Global Orphan Drugs Market by Drug Type, Performance - Potential Analysis
5.3. Global Orphan Drugs Market Estimates & Forecasts by Drug Type 2020-2030 (USD Billion)
5.4. Orphan Drugs Market, Sub Segment Analysis
5.4.1. Biological
5.4.2. Non-biological
CHAPTER 6. GLOBAL ORPHAN DRUGS MARKET, BY TOP SELLING DRUGS
6.1. Market Snapshot
6.2. Global Orphan Drugs Market by Top Selling Drugs, Performance - Potential Analysis
6.3. Global Orphan Drugs Market Estimates & Forecasts by Top Selling Drugs 2020-2030 (USD Billion)
6.4. Orphan Drugs Market, Sub Segment Analysis
6.4.1. Revlimid
6.4.2. Darzalex
6.4.3. Rituxan
6.4.4. Tafinlar
6.4.5. Ninlaro
6.4.6. Other
CHAPTER 7. GLOBAL ORPHAN DRUGS MARKET, BY DISEASE TYPE
7.1. Market Snapshot
7.2. Global Orphan Drugs Market by Disease Type, Performance - Potential Analysis
7.3. Global Orphan Drugs Market Estimates & Forecasts by Disease Type 2020-2030 (USD Billion)
7.4. Orphan Drugs Market, Sub Segment Analysis
7.4.1. Oncology
7.4.2. Hematology
7.4.3. Neurology
7.4.4. Cardiovascular
7.4.5. Other Disease Types
CHAPTER 8. GLOBAL ORPHAN DRUGS MARKET, REGIONAL ANALYSIS
8.1. Top Leading Countries
8.2. Top Emerging Countries
8.3. Orphan Drugs Market, Regional Market Snapshot
8.4. North America Orphan Drugs Market
8.4.1. U.S. Orphan Drugs Market
8.4.1.1. Drug Type breakdown estimates & forecasts, 2020-2030
8.4.1.2. Top Selling Drugs breakdown estimates & forecasts, 2020-2030
8.4.1.3. Disease Type breakdown estimates & forecasts, 2020-2030
8.4.2. Canada Orphan Drugs Market
8.5. Europe Orphan Drugs Market Snapshot
8.5.1. U.K. Orphan Drugs Market
8.5.2. Germany Orphan Drugs Market
8.5.3. France Orphan Drugs Market
8.5.4. Spain Orphan Drugs Market
8.5.5. Italy Orphan Drugs Market
8.5.6. Rest of Europe Orphan Drugs Market
8.6. Asia-Pacific Orphan Drugs Market Snapshot
8.6.1. China Orphan Drugs Market
8.6.2. India Orphan Drugs Market
8.6.3. Japan Orphan Drugs Market
8.6.4. Australia Orphan Drugs Market
8.6.5. South Korea Orphan Drugs Market
8.6.6. Rest of Asia Pacific Orphan Drugs Market
8.7. Latin America Orphan Drugs Market Snapshot
8.7.1. Brazil Orphan Drugs Market
8.7.2. Mexico Orphan Drugs Market
8.8. Middle East & Africa Orphan Drugs Market
8.8.1. Saudi Arabia Orphan Drugs Market
8.8.2. South Africa Orphan Drugs Market
8.8.3. Rest of Middle East & Africa Orphan Drugs Market
CHAPTER 9. COMPETITIVE INTELLIGENCE
9.1. Key Company SWOT Analysis
9.1.1. Company
9.1.2. Company
9.1.3. Company
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. Alexion Pharmaceuticals Inc
9.3.1.1. Key Information
9.3.1.2. Overview
9.3.1.3. Financial (Subject to Data Availability)
9.3.1.4. Product Summary
9.3.1.5. Recent Developments
9.3.2. Bristol-Myers Squibb Company (Celgene Corporation)
9.3.3. Novartis AG
9.3.4. Pfizer Inc.
9.3.5. F. Hoffmann-La Roche Ltd
9.3.6. Takeda Pharmaceutical Company Limited
9.3.7. Amgen Inc.
9.3.8. Sanofi S.A
9.3.9. Johnson & Johnson Pvt Ltd
9.3.10. AstraZeneca Plc
CHAPTER 10. RESEARCH PROCESS
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
1.2.1. Orphan Drugs Market, by Region, 2020-2030 (USD Billion)
1.2.2. Orphan Drugs Market, by Drug Type, 2020-2030 (USD Billion)
1.2.3. Orphan Drugs Market, by Top Selling Drugs, 2020-2030 (USD Billion)
1.2.4. Orphan Drugs Market, by Disease Type, 2020-2030 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
CHAPTER 2. GLOBAL ORPHAN DRUGS MARKET DEFINITION AND SCOPE
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Industry Evolution
2.2.2. Scope of the Study
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
CHAPTER 3. GLOBAL ORPHAN DRUGS MARKET DYNAMICS
3.1. Orphan Drugs Market Impact Analysis (2020-2030)
3.1.1. Market Drivers
3.1.1.1. Rising Prevalence of Rare Diseases
3.1.1.2. Favorable Government Policies
3.1.2. Market Challenges
3.1.2.1. High Per Patient Treatment Cost
3.1.2.2. Limited Patient Pool for Clinical Trials and Product Marketing
3.1.3. Market Opportunities
3.1.3.1. Increasing research and development activities in the development of new therapies for rare diseases
3.1.3.2. Strong Product Launches activities
CHAPTER 4. GLOBAL ORPHAN DRUGS MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Porter’s 5 Force Impact Analysis
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.3.5. Environmental
4.3.6. Legal
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. COVID-19 Impact Analysis
4.7. Disruptive Trends
4.8. Industry Expert Perspective
4.9. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL ORPHAN DRUGS MARKET, BY DRUG TYPE
5.1. Market Snapshot
5.2. Global Orphan Drugs Market by Drug Type, Performance - Potential Analysis
5.3. Global Orphan Drugs Market Estimates & Forecasts by Drug Type 2020-2030 (USD Billion)
5.4. Orphan Drugs Market, Sub Segment Analysis
5.4.1. Biological
5.4.2. Non-biological
CHAPTER 6. GLOBAL ORPHAN DRUGS MARKET, BY TOP SELLING DRUGS
6.1. Market Snapshot
6.2. Global Orphan Drugs Market by Top Selling Drugs, Performance - Potential Analysis
6.3. Global Orphan Drugs Market Estimates & Forecasts by Top Selling Drugs 2020-2030 (USD Billion)
6.4. Orphan Drugs Market, Sub Segment Analysis
6.4.1. Revlimid
6.4.2. Darzalex
6.4.3. Rituxan
6.4.4. Tafinlar
6.4.5. Ninlaro
6.4.6. Other
CHAPTER 7. GLOBAL ORPHAN DRUGS MARKET, BY DISEASE TYPE
7.1. Market Snapshot
7.2. Global Orphan Drugs Market by Disease Type, Performance - Potential Analysis
7.3. Global Orphan Drugs Market Estimates & Forecasts by Disease Type 2020-2030 (USD Billion)
7.4. Orphan Drugs Market, Sub Segment Analysis
7.4.1. Oncology
7.4.2. Hematology
7.4.3. Neurology
7.4.4. Cardiovascular
7.4.5. Other Disease Types
CHAPTER 8. GLOBAL ORPHAN DRUGS MARKET, REGIONAL ANALYSIS
8.1. Top Leading Countries
8.2. Top Emerging Countries
8.3. Orphan Drugs Market, Regional Market Snapshot
8.4. North America Orphan Drugs Market
8.4.1. U.S. Orphan Drugs Market
8.4.1.1. Drug Type breakdown estimates & forecasts, 2020-2030
8.4.1.2. Top Selling Drugs breakdown estimates & forecasts, 2020-2030
8.4.1.3. Disease Type breakdown estimates & forecasts, 2020-2030
8.4.2. Canada Orphan Drugs Market
8.5. Europe Orphan Drugs Market Snapshot
8.5.1. U.K. Orphan Drugs Market
8.5.2. Germany Orphan Drugs Market
8.5.3. France Orphan Drugs Market
8.5.4. Spain Orphan Drugs Market
8.5.5. Italy Orphan Drugs Market
8.5.6. Rest of Europe Orphan Drugs Market
8.6. Asia-Pacific Orphan Drugs Market Snapshot
8.6.1. China Orphan Drugs Market
8.6.2. India Orphan Drugs Market
8.6.3. Japan Orphan Drugs Market
8.6.4. Australia Orphan Drugs Market
8.6.5. South Korea Orphan Drugs Market
8.6.6. Rest of Asia Pacific Orphan Drugs Market
8.7. Latin America Orphan Drugs Market Snapshot
8.7.1. Brazil Orphan Drugs Market
8.7.2. Mexico Orphan Drugs Market
8.8. Middle East & Africa Orphan Drugs Market
8.8.1. Saudi Arabia Orphan Drugs Market
8.8.2. South Africa Orphan Drugs Market
8.8.3. Rest of Middle East & Africa Orphan Drugs Market
CHAPTER 9. COMPETITIVE INTELLIGENCE
9.1. Key Company SWOT Analysis
9.1.1. Company
9.1.2. Company
9.1.3. Company
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. Alexion Pharmaceuticals Inc
9.3.1.1. Key Information
9.3.1.2. Overview
9.3.1.3. Financial (Subject to Data Availability)
9.3.1.4. Product Summary
9.3.1.5. Recent Developments
9.3.2. Bristol-Myers Squibb Company (Celgene Corporation)
9.3.3. Novartis AG
9.3.4. Pfizer Inc.
9.3.5. F. Hoffmann-La Roche Ltd
9.3.6. Takeda Pharmaceutical Company Limited
9.3.7. Amgen Inc.
9.3.8. Sanofi S.A
9.3.9. Johnson & Johnson Pvt Ltd
9.3.10. AstraZeneca Plc
CHAPTER 10. RESEARCH PROCESS
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption
LIST OF TABLES
TABLE 1. Global Orphan Drugs Market, report scope
TABLE 2. Global Orphan Drugs Market estimates & forecasts by Region 2020-2030 (USD Billion)
TABLE 3. Global Orphan Drugs Market estimates & forecasts by Drug Type 2020-2030 (USD Billion)
TABLE 4. Global Orphan Drugs Market estimates & forecasts by Top Selling Drugs 2020-2030 (USD Billion)
TABLE 5. Global Orphan Drugs Market estimates & forecasts by Disease Type 2020-2030 (USD Billion)
TABLE 6. Global Orphan Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 7. Global Orphan Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 8. Global Orphan Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 9. Global Orphan Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 10. Global Orphan Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 11. Global Orphan Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 12. Global Orphan Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 13. Global Orphan Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 14. Global Orphan Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 15. Global Orphan Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 16. U.S. Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 17. U.S. Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 18. U.S. Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 19. Canada Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 20. Canada Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 21. Canada Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 22. UK Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 23. UK Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 24. UK Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 25. Germany Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 26. Germany Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 27. Germany Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 28. France Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 29. France Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 30. France Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 31. Italy Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 32. Italy Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 33. Italy Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 34. Spain Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 35. Spain Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 36. Spain Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 37. RoE Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 38. RoE Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 39. RoE Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 40. China Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 41. China Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 42. China Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 43. India Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 44. India Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 45. India Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 46. Japan Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 47. Japan Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 48. Japan Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 49. South Korea Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 50. South Korea Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 51. South Korea Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 52. Australia Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 53. Australia Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 54. Australia Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 55. RoAPAC Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 56. RoAPAC Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 57. RoAPAC Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 58. Brazil Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 59. Brazil Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 60. Brazil Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 61. Mexico Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 62. Mexico Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 63. Mexico Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 64. RoLA Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 65. RoLA Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 66. RoLA Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 67. Saudi Arabia Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 68. South Africa Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 69. RoMEA Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 70. List of secondary sources, used in the study of global Orphan Drugs Market
TABLE 71. List of primary sources, used in the study of global Orphan Drugs Market
TABLE 72. Years considered for the study
TABLE 73. Exchange rates considered
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
TABLE 1. Global Orphan Drugs Market, report scope
TABLE 2. Global Orphan Drugs Market estimates & forecasts by Region 2020-2030 (USD Billion)
TABLE 3. Global Orphan Drugs Market estimates & forecasts by Drug Type 2020-2030 (USD Billion)
TABLE 4. Global Orphan Drugs Market estimates & forecasts by Top Selling Drugs 2020-2030 (USD Billion)
TABLE 5. Global Orphan Drugs Market estimates & forecasts by Disease Type 2020-2030 (USD Billion)
TABLE 6. Global Orphan Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 7. Global Orphan Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 8. Global Orphan Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 9. Global Orphan Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 10. Global Orphan Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 11. Global Orphan Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 12. Global Orphan Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 13. Global Orphan Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 14. Global Orphan Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 15. Global Orphan Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 16. U.S. Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 17. U.S. Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 18. U.S. Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 19. Canada Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 20. Canada Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 21. Canada Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 22. UK Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 23. UK Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 24. UK Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 25. Germany Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 26. Germany Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 27. Germany Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 28. France Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 29. France Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 30. France Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 31. Italy Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 32. Italy Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 33. Italy Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 34. Spain Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 35. Spain Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 36. Spain Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 37. RoE Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 38. RoE Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 39. RoE Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 40. China Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 41. China Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 42. China Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 43. India Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 44. India Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 45. India Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 46. Japan Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 47. Japan Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 48. Japan Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 49. South Korea Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 50. South Korea Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 51. South Korea Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 52. Australia Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 53. Australia Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 54. Australia Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 55. RoAPAC Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 56. RoAPAC Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 57. RoAPAC Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 58. Brazil Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 59. Brazil Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 60. Brazil Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 61. Mexico Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 62. Mexico Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 63. Mexico Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 64. RoLA Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 65. RoLA Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 66. RoLA Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 67. Saudi Arabia Orphan Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 68. South Africa Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 69. RoMEA Orphan Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 70. List of secondary sources, used in the study of global Orphan Drugs Market
TABLE 71. List of primary sources, used in the study of global Orphan Drugs Market
TABLE 72. Years considered for the study
TABLE 73. Exchange rates considered
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
LIST OF FIGURES
FIG 1. Global Orphan Drugs Market, research methodology
FIG 2. Global Orphan Drugs Market, Market estimation techniques
FIG 3. Global Market size estimates & forecast methods
FIG 4. Global Orphan Drugs Market, key trends 2022
FIG 5. Global Orphan Drugs Market, growth prospects 2023-2030
FIG 6. Global Orphan Drugs Market, porters 5 force model
FIG 7. Global Orphan Drugs Market, pest analysis
FIG 8. Global Orphan Drugs Market, value chain analysis
FIG 9. Global Orphan Drugs Market by segment, 2020 & 2030 (USD Billion)
FIG 10. Global Orphan Drugs Market by segment, 2020 & 2030 (USD Billion)
FIG 11. Global Orphan Drugs Market by segment, 2020 & 2030 (USD Billion)
FIG 12. Global Orphan Drugs Market by segment, 2020 & 2030 (USD Billion)
FIG 13. Global Orphan Drugs Market by segment, 2020 & 2030 (USD Billion)
FIG 14. Global Orphan Drugs Market, regional snapshot 2020 & 2030
FIG 15. North America Orphan Drugs Market 2020 & 2030 (USD Billion)
FIG 16. Europe Orphan Drugs Market 2020 & 2030 (USD Billion)
FIG 17. Asia pacific Orphan Drugs Market 2020 & 2030 (USD Billion)
FIG 18. Latin America Orphan Drugs Market 2020 & 2030 (USD Billion)
FIG 19. Middle East & Africa Orphan Drugs Market 2020 & 2030 (USD Billion)
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
FIG 1. Global Orphan Drugs Market, research methodology
FIG 2. Global Orphan Drugs Market, Market estimation techniques
FIG 3. Global Market size estimates & forecast methods
FIG 4. Global Orphan Drugs Market, key trends 2022
FIG 5. Global Orphan Drugs Market, growth prospects 2023-2030
FIG 6. Global Orphan Drugs Market, porters 5 force model
FIG 7. Global Orphan Drugs Market, pest analysis
FIG 8. Global Orphan Drugs Market, value chain analysis
FIG 9. Global Orphan Drugs Market by segment, 2020 & 2030 (USD Billion)
FIG 10. Global Orphan Drugs Market by segment, 2020 & 2030 (USD Billion)
FIG 11. Global Orphan Drugs Market by segment, 2020 & 2030 (USD Billion)
FIG 12. Global Orphan Drugs Market by segment, 2020 & 2030 (USD Billion)
FIG 13. Global Orphan Drugs Market by segment, 2020 & 2030 (USD Billion)
FIG 14. Global Orphan Drugs Market, regional snapshot 2020 & 2030
FIG 15. North America Orphan Drugs Market 2020 & 2030 (USD Billion)
FIG 16. Europe Orphan Drugs Market 2020 & 2030 (USD Billion)
FIG 17. Asia pacific Orphan Drugs Market 2020 & 2030 (USD Billion)
FIG 18. Latin America Orphan Drugs Market 2020 & 2030 (USD Billion)
FIG 19. Middle East & Africa Orphan Drugs Market 2020 & 2030 (USD Billion)
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
